{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-250656","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.981415+00:00","generated_at":"2026-05-17T02:13:43.985827+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neumora reports NMRA-215 preclinical data: up to 19% monotherapy weight loss, 26% with semaglutide","bullets":["NMRA-215 showed class-leading 19% weight loss as monotherapy with semaglutide-like induction in DIO mice.","Combination with high-dose semaglutide achieved up to 26% weight loss, best-in-class vs. NLRP3 inhibitors.","Preclinical data support potential as oral, brain-penetrant NLRP3 inhibitor for obesity.","Neumora plans to initiate Phase 1 clinical study for NMRA-215 in Q1 2026.","Additional data to be presented at virtual R&D day on October 27, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-250656","json":"https://secwatch.observer/filing/0001193125-25-250656.json","markdown":"https://secwatch.observer/filing/0001193125-25-250656.md","text":"https://secwatch.observer/filing/0001193125-25-250656.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525250656/0001193125-25-250656-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525250656/nmra-20251027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:13:43.985827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}